Weekly Recap: Phase 3 ZENITH AD trials and $90M jury award

Nektar Therapeutics (NASDAQ:NKTR) is advancing rezpegaldesleukin with two global Phase 3 ZENITH AD trials (a third planned) even as Wedbush flags safety/efficacy concerns and a $50 target, the company won a $90M jury award and granted inducement equity to new hires.Previous Week RecapThis is an AI…